Health care reforms should be more focused on eliminating waste by becoming more efficient and putting patients first.

While the FDAneeds tochange to respond to innovations in cancer therapies, regulators must maintain safeguards on drug approval.

In the recent case of Abigail Alliance v. von Eschenbach, a divided panel of the United States Court of Appeals for the D.C. Circuit held that the due process clause required the Food and Drug Administration (FDA) to allow terminally ill patients the opportunity to use last-hope drugs that have...

It's time for Plan C. Clinton and her allies should let the Senate vote on the von Eschenbach nomination.

While controversy has raged over the Food and Drug Administration's (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA's role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...

While controversy has raged over the Food and Drug Administration’s (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA’s role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...

President Obama's FDA commissioner should avoid actions that make the drug development process more costly and inefficient.

Will2006 and 2008 present major opportunities for the Democrats? Or are election results the foundation for building a governing Republican majority that will last at least a generation?